RATIONALE: The psychostimulant drugs cocaine and methamphetamine are potent indirect dopamine receptor agonists which act through similar but not identical mechanisms. Studies in humans have observed that a large proportion of those who chronically use these drugs experience psychotic symptoms. However, direct comparisons of psychotic symptom severity between cocaine and methamphetamine users are lacking. OBJECTIVES: The goal of the present study was to directly compare severity of psychotic symptoms between cocaine- and methamphetamine-dependent individuals. Additionally, we sought to determine how concurrent cocaine + methamphetamine dependence would influence psychotic symptoms. METHODS: We recruited 153 polysubstance-using subjects meeting DSM-IV-TR criteria for cocaine dependence, 38 with methamphetamine dependence, and 32 with cocaine + methamphetamine dependence. Psychotic symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS) and analyzed using a five-factor model. All participants were also assessed for physical and mental illnesses as well as recent substance use. Most subjects completed a comprehensive neurocognitive battery. RESULTS: While all three groups exhibited high total PANSS scores, the positive symptom subscale was significantly higher in the methamphetamine-dependent (17.03 ± 6.3) than the cocaine-dependent group (13.51 ± 4.12) and non-significantly higher (p = 0.08) than the cocaine + methamphetamine group (14.44 ± 5.50). Groups also differed on demographic variables, viral infection, and other indices of substance use, which were unlikely to account for the difference in positive symptoms. There were only modest differences between groups in neurocognitive function. CONCLUSIONS: Methamphetamine dependence was associated with more severe positive symptoms of psychosis than cocaine dependence. Concurrent cocaine + methamphetamine dependence did not increase psychosis severity.
RATIONALE: The psychostimulant drugs cocaine and methamphetamine are potent indirect dopamine receptor agonists which act through similar but not identical mechanisms. Studies in humans have observed that a large proportion of those who chronically use these drugs experience psychotic symptoms. However, direct comparisons of psychotic symptom severity between cocaine and methamphetamine users are lacking. OBJECTIVES: The goal of the present study was to directly compare severity of psychotic symptoms between cocaine- and methamphetamine-dependent individuals. Additionally, we sought to determine how concurrent cocaine + methamphetamine dependence would influence psychotic symptoms. METHODS: We recruited 153 polysubstance-using subjects meeting DSM-IV-TR criteria for cocaine dependence, 38 with methamphetamine dependence, and 32 with cocaine + methamphetamine dependence. Psychotic symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS) and analyzed using a five-factor model. All participants were also assessed for physical and mental illnesses as well as recent substance use. Most subjects completed a comprehensive neurocognitive battery. RESULTS: While all three groups exhibited high total PANSS scores, the positive symptom subscale was significantly higher in the methamphetamine-dependent (17.03 ± 6.3) than the cocaine-dependent group (13.51 ± 4.12) and non-significantly higher (p = 0.08) than the cocaine + methamphetamine group (14.44 ± 5.50). Groups also differed on demographic variables, viral infection, and other indices of substance use, which were unlikely to account for the difference in positive symptoms. There were only modest differences between groups in neurocognitive function. CONCLUSIONS:Methamphetamine dependence was associated with more severe positive symptoms of psychosis than cocaine dependence. Concurrent cocaine + methamphetamine dependence did not increase psychosis severity.
Authors: Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson Journal: Annu Rev Pharmacol Toxicol Date: 2007 Impact factor: 13.820
Authors: Kristina M Gicas; Fidel Vila-Rodriguez; Karine Paquet; Alasdair M Barr; Ric M Procyshyn; Donna J Lang; Geoffrey N Smith; Heather A Baitz; Chantelle J Giesbrecht; Julio S Montaner; Mel Krajden; Michael Krausz; G William MacEwan; William J Panenka; William G Honer; Allen E Thornton Journal: J Clin Exp Neuropsychol Date: 2014-11-07 Impact factor: 2.475
Authors: Rasmon Kalayasiri; Atapol Sughondhabirom; Ralitza Gueorguieva; Vladimir Coric; Wendy J Lynch; Peter T Morgan; Joseph F Cubells; Robert T Malison Journal: Pharmacol Biochem Behav Date: 2006-03-20 Impact factor: 3.533
Authors: Ellen A A van der Plas; Eveline A Crone; Wery P M van den Wildenberg; Daniel Tranel; Antoine Bechara Journal: J Clin Exp Neuropsychol Date: 2008-11-26 Impact factor: 2.475
Authors: Taylor S Willi; Alasdair M Barr; Kristina Gicas; Donna J Lang; Fidel Vila-Rodriguez; Wayne Su; Allen E Thornton; Olga Leonova; Chantelle J Giesbrecht; Ric M Procyshyn; Alexander Rauscher; William G MacEwan; William G Honer; William J Panenka Journal: Addict Biol Date: 2016-02-01 Impact factor: 4.280
Authors: Peter D Alexander; Kristina M Gicas; Alex Cheng; Donna J Lang; Ric M Procyshyn; Alexandra T Vertinsky; William J Panenka; Allen E Thornton; Alexander Rauscher; Jamie Y X Wong; Tasha Chan; Andrea A Jones; F Vila-Rodriguez; William G Honer; Alasdair M Barr Journal: Psychopharmacology (Berl) Date: 2019-06-22 Impact factor: 4.530
Authors: Jade C Yau; Shu Min Yu; William J Panenka; Hadley Pearce; Kristina M Gicas; Ric M Procyshyn; Caroline MacCallum; William G Honer; Alasdair M Barr Journal: BMC Psychiatry Date: 2019-11-01 Impact factor: 3.630